Davis Polk advised the joint book-running managers in connection with a $20 million SEC-registered common stock offering by Sienna Biopharmaceuticals, Inc. The common stock is listed…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now